AbbVie Reports 2025 Financial Results and 2026 Outlook

Details

The company reported full-year GAAP diluted EPS of $2.36, a decrease of 1.3 percent. AbbVie provided a 2026 adjusted diluted EPS guidance range of $14.37 to $14.57. Notable product performance included significant growth in Skyrizi and Rinvoq revenues, while Humira saw a substantial decline. Recent regulatory events included FDA approval of Epkinly for the treatment of relapsed or refractory follicular lymphoma.

Items reported

About AbbVie Inc.

AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.